Adcetris (brentuximab vedotin) / Takeda, Pfizer - LARVOL DELTA

Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study. (PubMed, Lancet Haematol) - P2 | "In patients with mostly CD30-expressing peripheral T-cell lymphomas other than non-anaplastic large-cell lymphoma, CHEP-BV (with or without autologous HSCT) followed by brentuximab vedotin consolidation was safe and active."

Journal • P2 data • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • Transplantation • TNFRSF8

Real-world treatment patterns and outcomes of brentuximab vedotin-based therapy in CD30-positive lymphomas in China: the prospective BRAVE study. (PubMed, Blood Cancer J) - No abstract available

HEOR • Journal • Real-world evidence • Hematological Malignancies • Lymphoma • Oncology • TNFRSF8

Brentuximab vedotin-induced pustular eruption in transformed mycosis fungoides: a diagnostic challenge (EADV 2026) - "Prior mogamulizumab exposure has been associated with earlier onset of brentuximab vedotin-related rash, a pattern also seen in our patient, who developed the eruption 38 days after initiation (reported median of 43 days). Severe skin reactions to brentuximab vedotin are exceptional but must be recognized, as they can be mistaken for a flare of the tumoral disease."

Cutaneous T-cell Lymphoma • Dermatology • Eosinophilia • Mycosis Fungoides • Oncology • TNFRSF8

Intralesional Methotrexate for the Treatment of Thick Plaque Mycosis Fungoides: Revisiting an Underutilized Classic (EADV 2026) - "Other treatments include brentuximab, mogamulizumab, chemotherapy, and stem cell transplantation...During his treatment course, the patient was referred to hemato-ocology and low dose gemcitabine in six cycles was given...In the case presented, it was shown effective in thick plaques with large cell transformation. Methotrexate is an easy and available option that can be utilized in recalcitrant isolated plaques and tumors and in transformation."

Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology

Golidocitinib Plus Brentuximab Vedotin for Brentuximab Vedotin-Refractory/Relapsed Advanced Folliculotropic Mycosis Fungoides and Sézary Syndrome: A Retrospective Cohort Study (EADV 2026) - "Responses appeared more pronounced in patients with low CD30 expression, suggesting a potential role of JAK1 inhibition in overcoming BV resistance. These findings support further prospective studies to validate Go-BV as a therapeutic strategy in advanced CTCL."

Late-breaking abstract • Metastases • Retrospective data • Cutaneous T-cell Lymphoma • Cytomegalovirus Infection • Dermatology • Dyslipidemia • Hematological Disorders • Hypertriglyceridemia • Infectious Disease • Leukopenia • Mycosis Fungoides • Oncology • Pruritus • Sezary Syndrome • Thrombocytopenia • TNFRSF8

Bridging the Evidence Gap in Advanced MF/SS: Stage-Stratified Treatment Patterns and Outcomes from PROCLIPI (EADV 2026) - P | "The most common first-line systemic therapies were extracorporeal photopheresis (ECP) (22.0%), methotrexate (16.8%), interferon-alpha (16.8%) and bexarotene (16.1%), together accounting for 71.7% of 410 first-line systemic treatments...The highest first-line ORRs were seen with gemcitabine (78%), romidepsin (60%) and brentuximab vedotin (60%)...Mogamulizumab achieved the highest second-line ORR (79%, n=29; median TTNsT 11.6 months), whereas the gemcitabine response rate fell from 78% at first line to 38% at second line...Sequential treatment exposure and the prevalence of combination regimens preclude attribution of overall survival to individual agents; longer follow-up and confounder-adjusted analyses will be required. Our analysis underscores the complexity of disease management and supports the need for stage-adapted treatment strategies informed by real-world prospective evidence to optimise sequencing and outcomes in this challenging patient population."

Metastases • Cutaneous T-cell Lymphoma • Dermatopathology • Mycosis Fungoides • Oncology • Sezary Syndrome • Skin Cancer

Clinical characteristics and treatment outcomes assessed by time to next treatment in 136 patients with mycosis fungoides : a single-center retrospective study (ESDR 2026) - "Median TTNT was 24 months for bexarotene (n=38), 16 months for etretinate (n=27), 20 months for systemic interferon-γ (n=10), 26 months for brentuximab vedotin (n=4), 3.5 months for forodesine (n=4), 10 months for etoposide (n=3), and 1.5 months for denileukin diftitox (n=2). Median TTNT was not reached for mogamulizumab (n=7)...TTNT summarized real-world treatment continuation across systemic therapies for MF. The prolonged TTNT observed in some agents may partly reflect combination therapy."

Late-breaking abstract • Retrospective data • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • T Cell Non-Hodgkin Lymphoma • IFNG

Differential Nephrotoxicity of Antibody-Drug Conjugate Payloads: A Propensity Score-Matched Analysis of Monomethyl Auristatin E vs. Topoisomerase I Inhibitors (KIDNEY WEEK 2026) - "Reports for five major ADCs were grouped by payload: MMAE (enfortumab, polatuzumab, brentuximab) vs. Topo-I controls (sacituzumab, trastuzumab deruxtecan). Conclusion This propensity-matched analysis demonstrates that ADC-associated nephrotoxicity is an independent class effect of the MMAE payload, not merely an artifact of the urothelial cancer population. Payload class serves as a critical risk stratification tool, warranting intensive renal monitoring for patients receiving MMAE therapies."

ADC • Acute Kidney Injury • Bladder Cancer • Breast Cancer • Genito-urinary Cancer • Nephrology • Renal Disease • Solid Tumor • Urothelial Cancer • TOP1

A Challenging Case of IgAN and Vasculitis Complicating Nivolumab Therapy for Hodgkin Lymphoma (KIDNEY WEEK 2026) - "Case Description A 40-year-old female with Hodgkin lymphoma treated with cyclophosphamide/vincristine, now on brentuximab-nivolumab, developed a diffuse rash...Nivolumab was discontinued, and corticosteroids and losartan were initiated...The challenge lies in attributing the IgA vasculitis to nivolumab versus the underlying malignancy, as lymphoma recurrence raises the possibility of paraneoplastic pathogenesis and improvement in proteinuria after SCT favors a paraneoplastic mechanism, although we are unable to rule out nivolumab involvement. This case highlights the importance of screening for proteinuria and hematuria in patients who are receiving ICIs and introduces the clinical dilemma when ICI discontinuation due to nephrotoxicity compromises oncologic outcomes."

Clinical • Fibrosis • Glomerulonephritis • Hematological Malignancies • Hodgkin Lymphoma • IgA Nephropathy • Immunology • Lupus Nephritis • Lymphoma • Nephrology • Renal Disease • Vasculitis

Sustained CAR T-cell viability and function in the presence of Brentuximab Vedotin treatment in vitro supports potential combination or sequential therapy approaches in lymphoma (SITC 2026) - No abstract available

CAR T-Cell Therapy • Preclinical • Hematological Malignancies • Lymphoma • Oncology

Immunotherapy-Based Therapies in Pediatric Hodgkin Lymphoma: Potential to Narrow the Gap in Long-Term Survival. (PubMed, J Natl Cancer Inst) - "We developed a simulation model to project lifetime outcomes after contemporary brentuximab vedotin- or nivolumab-containing regimens using trial data (COG AHOD1331 and SWOG S1826), Childhood Cancer Survivor Study data, and national databases. Survival gains persisted unless immunotherapy-related late mortality exceeded approximately 8%. These projections suggest contemporary regimens may narrow the long-term survival gap while reducing late-effect burden."

Journal • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Pediatrics

Five-year results of short-course brentuximab vedotin combined with chemotherapy and radiation in early stage, unfavorable Hodgkin lymphoma. (PubMed, Haematologica) - "Not available."

Journal • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. (PubMed, N Engl J Med) - P3 | "Patients who received A+AVD for the treatment of stage III or IV Hodgkin's lymphoma had a survival advantage over those who received ABVD. (Funded by Takeda Development Center Americas and Seagen; ECHELON-1 ClinicalTrials.gov number, NCT01712490; EudraCT number, 2011-005450-60.)."

Journal • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology • Pain • Transplantation

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. (PubMed, N Engl J Med) - P3 | "N+AVD resulted in longer progression-free survival than BV+AVD in adolescents and adults with stage III or IV advanced-stage classic Hodgkin's lymphoma and had a better side-effect profile. (Funded by the National Cancer Institute of the National Institutes of Health and others; S1826 ClinicalTrials.gov number, NCT03907488.)."

Clinical • Journal • Metastases • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Pediatrics

Open Label Extension Study of Brentuximab Vedotin in Early dcSSc (clinicaltrials.gov) - P2 | N=3 | Completed | Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | N=11 ➔ 3 | Recruiting ➔ Completed

Enrollment change • Trial completion • Immunology • Scleroderma • Systemic Sclerosis

Duality of Rarity of Chemotherapy-induced Flagellate Erythema among Cancer Patients: A Case Report with 26 Years of Evidence in Oncology. (PubMed, Curr Drug Saf) - "Healthcare professionals should be aware of and vigilant for this whip-like dermatological manifestation (FD) when choosing Bleomycin-based therapy. A patient-centric approach to cessation or rechallenge with the culprit drug, along with antihistamines and topical/ oral corticosteroids, is the mainstay for the management of FD."

Journal • Cough • Dermatitis • Dermatology • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Oncology • Respiratory Diseases

Intralesional Biologics in Dermatology: A Systematic Review (EADV 2026) - "Rituximab was the most frequently reported intralesional biologic, while other agents included adalimumab, dupilumab, brentuximab vedotin, spesolimab, secukinumab, guselkumab, bevacizumab, nivolumab, talimogene laherparepvec, and interleukin-2-based therapies. However, the currently available evidence is limited by marked heterogeneity and the predominance of low-level evidence, especially case reports. Further prospective and controlled studies are needed to better define efficacy, safety, optimal dosing strategies, and the most appropriate indications for intralesional biologic therapy in dermatology."

Review • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Extranodal Marginal Zone Lymphoma • Fibrosis • Hematological Malignancies • Immunology • Kaposi Sarcoma • Lichen Planus • Lymphoma • Marginal Zone Lymphoma • Melanoma • Mucosal Melanoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Ocular Inflammation • Pemphigus Vulgaris • Prurigo Nodularis • Psoriasis • Sarcoidosis • Sarcoma • Solid Tumor • IL2

Drug Rash with Eosinophilia and Systemic Symptoms Associated with Brentuximab Vedotin: A Rarely Reported Case in the Literature (EADV 2026) - "Following the diagnosis, chemotherapy with adriamycin, bleomycin, vinblastine, and dacarbazine was initiated...In consensus with the hematologydepartment, it was decided to continue brentuximab treatment, initiate systemic methylprednisolone at a dose of 32 mg/day, apply mometasone furoateointment to the erythematous maculopapular lesions on the arms and legs, and closely monitor liver and kidney function tests as well as hemogramparameters...It typically develops 2–6 weeks after exposure to the offending drug, with antiepileptics, antibiotics, NSAIDs, and allopurinol being the most frequently implicated agents...Although brentuximab vedotin is known to cause various cutaneous adverse reactions, DRESS associated with this agent has been reported only rarely. This case highlights the importance of recognizing DRESS in patients receiving brentuximab vedotin who develop fever, rash, and systemic involvement, emphasizing the need for early diagnosis and prompt treatment to..."

Clinical • Cardiovascular • Cutaneous T-cell Lymphoma • Eosinophilia • Hematological Malignancies • Immunology • Lymphoma • T Cell Non-Hodgkin Lymphoma • TNFRSF8

Persistent alopecia following brentuximab vedotin–containing chemotherapy: a survivorship issue with significant psychosocial impact (ESMO 2026) - No abstract available

Oncology

Sequential lymphoid neoplasms mimicking relapse of mediastinal grey zone lymphoma in a patient with germline variants in EP300 and PTPRK. (PubMed, Virchows Arch) - "Interestingly, the shared variants were likely germline rather than clonal, suggesting they created a permissive background predisposing to two independent transforming events along the B- and T-cell lineages. Molecular studies may help to reveal the genetic basis of composite lymphomas and to resolve diagnostically discordant, complex presentations."

Journal • Hematological Malignancies • Lymphoma • Oncology • Skin Cancer • BTG2 • EP300 • JAK1 • NFKBIA • PTPRK

E4412: Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=146 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2026 ➔ Jun 2027 | Trial primary completion date: Dec 2026 ➔ Jun 2027

Trial completion date • Trial primary completion date • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • CD4

Diagnostic Value of [¹⁸F]FDG PET/CT in Immunotherapy-Related Meningoencephalitis: A Paediatric Case Report (EANM 2026) - "Materials and We report the case of a 15-year-old boy diagnosed with classical Hodgkin lymphoma undergoing second-line chemotherapy with brentuximab and nivolumab, who presented to the emergency department with headache and vomiting. This case highlights the complementary role of [¹⁸F]FDG PET/CT in the evaluation of indeterminate MRI findings in neuro-oncological patients. In line with existing literature, [18F]FDG PET/CT may detect and characterize metabolic alterations associated with immune-related neurotoxicity, supporting the differential diagnosis and contributing to treatment response assessment. Its integration into the diagnostic pathway may enhance clinical decision-making in complex cases."

Case report • Clinical • FDG PET • Classical Hodgkin Lymphoma • CNS Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Pediatrics

Real-world outcomes of nivolumab-AVD and brentuximab vedotin-AVD in paediatric and adult advanced-stage Hodgkin lymphoma. (PubMed, Br J Haematol) - "Brentuximab vedotin (BV)-doxorubicin, vinblastine and dacarbazine (AVD) and nivolumab (N)-AVD have transformed the frontline treatment of advanced-stage Hodgkin lymphoma (HL), yet real-world comparative data remain limited. Survival outcomes were consistent in a 1:1 propensity score-matched cohort. These real-world data demonstrate comparable survival between regimens, with numerically improved PFS supporting N-AVD as a frontline standard for advanced-stage HL; however, higher rates of neutropenia and infections warrant careful monitoring and consideration of growth factor prophylaxis."

Journal • Real-world evidence • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia • Oncology • Pain • Pediatrics

Primary Cutaneous Lymphomas and Lymphoproliferative Disorders: Current Insights for Classification and Management. (PubMed, Cancers (Basel)) - "Integrating the updated diagnostic classifications with modern risk-stratified and targeted treatment paradigms is crucial for optimizing clinical management and avoiding overtreatment in indolent PCLs while improving survival in aggressive subtypes."

Journal • Review • B Cell Lymphoma • Cutaneous T-cell Lymphoma • Dermatology • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type • T Cell Non-Hodgkin Lymphoma • CD4 • CD8

Primary ALK-positive anaplastic large cell lymphoma of the urinary bladder in a pediatric patient: a case report and review of literature. (PubMed, J Hematop) - "Primary bladder ALK + ALCL is exceedingly rare in children. Uniform CD30 positivity and ALK positivity are the key diagnostic clues."

Journal • Review • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pain • Pediatrics • Urology • ALK • CD5 • PTPRC • TNFRSF8